Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6159875
Reference Type
Journal Article
Title
Dr. Jonas Salk
Author(s)
Kleiss, KM
Year
2003
Volume
10
Issue
3
Page Numbers
127-128
DOI
10.1016/S1068-607X(03)00007-6
URL
http://www.sciencedirect.com/science/article/pii/S1068607X03000076
Exit
Abstract
Jonas Salk began his career in microbiology working with the inactivated influenza vaccine. He would later use the formalin inactivation process to create the poliomyelitis vaccine. Using a newly created modern cell culture technique, Salk was able to mass produce vaccines for the large-scale polio vaccine field trial. Under the direction of Thomas Francis, Jr., the field trial utilized both a double-blinded placebo-controlled trial and an observational study, and included almost 2 million American schoolchildren as subjects. The vaccine proved to be both safe and effective. Although later replaced by the Sabin oral vaccine, the Salk inactivated vaccine played a large part in the eventual eradication of polio from the Western Hemisphere. After his work on the polio vaccine, he created the Salk Institute, a private institution dedicated to research. Subsequently, until his death in 1995, Salk conducted research on an HIV vaccine.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity